AID⁺ CLL is correlated with an increased number of cytogenetic aberrations and worse clinical outcomes. Clinical data and prognostic factors for AID⁺ and AID⁻ CLL patients were compared using the Kaplan-Meier method. (A) TFT curves comparing AID⁺ and AID⁻ CLL patients (n = 58 and n = 55, respectively) were significantly different. **P = .0023. (B) OS curve of AID⁺ CLL patients (n = 57) differed significantly from that of AID⁻ patients (n = 55) ***P < .0001. (C) Age of CLL diagnosis curves of AID⁺ and AID⁻ CLL patients were not significantly different (n/s). (D) Age of death curve for AID⁺ CLL patients differed significantly from that of AID⁻ patients. ***P < .0001. (E) U-CLL patients were more frequently AID⁺ (38/55), whereas M-CLL patients were more frequently AID⁻ (54 of 66). ***P = .0001. (F) OS curve of AID⁺ M-CLL patients differed significantly from that of AID⁻ M-CLL patients. *P = .0264. (G) OS curves of AID⁺ and AID⁻ U-CLL patients were not significantly different (n/s). (H) AID⁺ patients had increased numbers of aberrations at 7 commonly tested cytogenetic loci (17p13.1, 11q22.3, 12-CEN, 13q34, 11q13, 14q32, and 6q23.3) compared with AID⁻ patients (median = 1 vs 0). Distribution of the numbers of aberrations was significantly different between the AID⁺ and AID⁻ groups. ***P = .0009.